Formulation and Profile of FMX101 4% Minocycline Topical Foam for the Treatment of Acne Vulgaris

FMX101 4% minocycline is a hydrophobic, topical foam formulation of minocycline recently approved by the United States Food and Drug Administration (FDA) for the treatment of non-nodular inflammatory lesions in moderate-to-severe acne vulgaris. It was developed to harness the anti-inflammatory and a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Aesthet Dermatol
Autores principales: Kircik, Leon, Del Rosso, James Q, Weiss, Jonathan S, Stakias, Vassilis, London, Anat, Keynan, Rita, Hazot, Yohan, Elliott, Russell, Stuart, Iain
Formato: Artigo
Lenguaje:Inglês
Publicado: Matrix Medical Communications 2020
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7605387/
https://ncbi.nlm.nih.gov/pubmed/33144907
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares